Repare Therapeutics Target of Unusually Large Options Trading (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of unusually large options trading on Wednesday. Investors acquired 3,187 call options on the company. This is an increase of approximately 407% compared to the typical daily volume of 629 call options.

Institutional Trading of Repare Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Affinity Asset Advisors LLC grew its position in shares of Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after purchasing an additional 100,000 shares in the last quarter. Acadian Asset Management LLC grew its stake in Repare Therapeutics by 35.6% during the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after buying an additional 168,230 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new stake in Repare Therapeutics during the second quarter worth about $56,000. XTX Topco Ltd bought a new position in Repare Therapeutics in the 2nd quarter valued at about $60,000. Finally, Militia Capital Partners LP acquired a new position in shares of Repare Therapeutics in the 2nd quarter valued at approximately $166,000. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Price Performance

RPTX opened at $2.57 on Thursday. The business has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $1.74. Repare Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.66. The company has a market capitalization of $110.79 million, a PE ratio of -1.52 and a beta of 1.02.

Repare Therapeutics (NASDAQ:RPTX) last posted its earnings results on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to analyst estimates of $7.50 million. Equities analysts anticipate that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on RPTX. Cowen cut Repare Therapeutics to a “hold” rating in a research report on Monday, November 17th. TD Cowen cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright decreased their price objective on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.